Premium
Fimasartan increases glucose‐stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine
Author(s) -
Yang Ye Seul,
Lim Min Hyuk,
Lee Seong Ok,
Roh Eun,
Ahn Chang Ho,
Kwak Soo Heon,
Cho Young Min,
Kim Sungwan,
Mari Andrea,
Park Kyong Soo,
Jung Hye Seung
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13282
Subject(s) - medicine , amlodipine , type 2 diabetes , endocrinology , insulin resistance , insulin , blood pressure , metformin , crossover study , diabetes mellitus , homeostatic model assessment , placebo , alternative medicine , pathology
Aim To study the effects of angiotensin receptor blockers (ARBs) on insulin secretion in hypertensive patients with type 2 diabetes. Materials and methods A total of 41 patients were enrolled in this open‐label, active comparator‐controlled, crossover study. After a 2‐week run‐in period with amlodipine, the participants were assigned to receive either fimasartan (60–120 mg daily) or amlodipine (5–10 mg daily) for 16 weeks. Thereafter, they were treated with the other drug for another 16 weeks. Physical examinations and laboratory tests were performed before and after each treatment. Results Blood pressure, glycated haemoglobin and oral glucose tolerance test (OGTT) values were similar with each treatment. Fimasartan treatment significantly increased median (range) homeostatic assessment of β‐cell function values (49.9 [22.5–174.4] vs 46.9 [15.6–148.0]), area under the curve of insulin during OGTT (27 284 [9501–94 525] vs 26 818 [8112–76 704] pmol/L × min), insulinogenic index at 60 minutes (19.7 [3.0–131.2] vs 15.0 [2.4–103.8] pmol/mmol) and at 120 minutes (19.1 [1.9–85.5] vs 12.6 [−4.3–178.8] pmol/mmol) compared with those with amlodipine (all P < .05); however, acute insulin response and insulin resistance indices were similar for both agents. Conclusions Compared with amlodipine, fimasartan increased late‐phase glucose‐stimulated insulin secretion in patients with type 2 diabetes and hypertension. This finding suggests that ARBs would be more beneficial in such patients compared with other classes of anti‐hypertensives.